81 – 90 of 98
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2006
-
Mark
Topoisomerase II{alpha} Gene Amplification Predicts Favorable Treatment Response to Tailored and Dose-Escalated Anthracycline-Based Adjuvant Chemotherapy in HER-2/neu-Amplified Breast Cancer: Scandinavian Breast Group Trial 9401.
(
- Contribution to journal › Article
- 2005
-
Mark
Topoisomerase IIa gene amplification predicts favorable outcome of tailored and dose-escalated anthracycline-based adjuvant chemotherapy in HER-2 positive breast cancer. Results from the randomized trial SBG 9401.
(
- Contribution to journal › Published meeting abstract
-
Mark
Coronary heart disease mortality after 5 years of adjuvant tamoxifen therapy: Results from a randomized trial
(
- Contribution to journal › Article
-
Mark
PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
(
- Contribution to journal › Article
-
Mark
Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials
(
- Contribution to journal › Article
-
Mark
The cost-effectiveness of post-operative radiotherapy after breast conservation surgery in stage I-II breast cancer in Sweden
(
- Contribution to journal › Published meeting abstract
- 2003
-
Mark
Prognostic value of quality of life scores for time to progression (TTP) and overall survival time (OS) in advanced breast cancer
(
- Contribution to journal › Article
-
Mark
Breast conservation surgery, with and without radiotherapy, in women with lymph node-negative breast cancer: a randomised clinical trial in a population with access to public mammography screening.
(
- Contribution to journal › Article
-
Mark
Psychological profile in patients with Stages I and II breast cancer: associations of psychological profile with tumor biological prognosticators.
(
- Contribution to journal › Article
- 2002
-
Mark
C-erbB-2 expression does not predict response to docetaxel or sequential methotrexate and 5-fluorouracil in advanced breast cancer
(
- Contribution to journal › Article